StockData

Clene vs Lexaria Bioscience

CLNN and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLNN and LEXX compare

Lexaria Bioscience is the larger company, worth 2.5 times as much as Clene ($104M against $41.4M).

Clene grew revenue faster over the last twelve months (−31.1% versus −68.5% for Lexaria Bioscience).

Lexaria Bioscience keeps more of each dollar of sales as profit, with a net margin of −3986% compared with −20060% at Clene.

Lexaria Bioscience scores higher on the StockData Score (8 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLNNLEXX
Size and price
Market cap$41.4M$104M
Share price$3.22$4.18
Change, 1 year−62.2%−73.7%
Change, 5 years−96.6%−94.8%
Beta (5Y)2.240.13
Employees79134
StockData Score
Total score18 (better)
Valuation score00
Growth score02 (better)
Performance score00
Health score16 (better)
Dividend score00
Valuation
P/S210× (better)534×
P/B–21.9×
FCF yield–−7.2%
Growth
Revenue growth (TTM)−31.1% (better)−68.5%
Revenue growth, 5Y average−0.59%17.5% (better)
Profitability
Gross margin70.1%100% (better)
Operating margin−10432%−3973% (better)
Net margin−20060%−3986% (better)
FCF margin–−3849%
Return on equity–−150%
Return on invested capital–−602%
Financial health
Debt / equity–0.00
Interest coverage−7.1×–
Current ratio3.0710.60 (better)
Altman Z-score−21.93117.82 (better)
Piotroski F-score22
Dividends and buybacks
Buyback yield–−6.3%
Shareholder yield0.00% (better)−6.3%
Ownership
Held by institutions24.8%–
Held by insiders45.9%3.0%
Insider net buying, 12 months−$5.6M–
Short interest, % of float6.0%0.90%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.